Fatemeh Heydari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fatemeh Heydari has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Afshin Gholipour Baradari
Department of Anesthesiology, School of Medicine, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
3 shared publicationsSeyyed Javad Boskabadi
Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
3 shared publicationsAbbas Alipour
Department of Community Medicine, Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Addiction Institute, Babolsar, Iran
2 shared publications- Mahmood Moosazadeh
Gastrointestinal Cancer Research Center, Non‐Communicable Disease Institute Mazandaran University of Medical Sciences Sari Iran
2 shared publications - Abbas Alipour
Community Medicine Department, Medical Faculty, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication Abolghasem Ajami
Department of Immunology, Faculty of Medicine, Antimicrobial Resistance Research Center, The Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Fatal methanol poisoning with paroxysmal sympathetic hyperactivity, and putaminal hemorrhage: a case report and brief literature review
- 7 August 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessFatal methanol poisoning with paroxysmal sympathetic hyperactivity, and putaminal hemorrhage: a case report and brief literature review
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 15 (1)
Effect of Ultra-low-dose Naloxone on Ileus after Cesarean Section: A Randomized Clinical Trial
Objective: Postoperative ileus commonly occurs after abdominal surgeries, often leading to longer hospital stays. While intravenous opioids are effective for pain management, they can extend ileus duration. Ultra-low-dose naloxone presents a promising strategy to improve pain control and minimize side effects. This study examines how ultra-low-dose naloxone impacts ileus after cesarean section. Methods: Seventy participants were randomly divided into two groups: 35 patients in the intervention group received a patient-controlled analgesia (PCA) pump with 30 mg of morphine, 0.25 μg/kg/h of naloxone, and saline, whereas 35 patients in the control group received morphine and saline only. Patients assessed their pain, nausea, and pruritus using a 0–10-point Visual Analog Scale upon arrival at the recovery room and then at 30 min, 60 min, 90 min, 120 min, 6 h, 12 h, and 24 h after surgery. We recorded the duration of ileus, time to tolerate liquids and solids, discharge timing, and analgesic consumption. Findings: The control group ( n = 35) experienced longer ileus duration ( P < 0.001), greater pain severity ( P = 0.02), and higher levels of nausea ( P = 0.04) and pruritus ( P = 0.02) compared to the intervention group ( n = 34). Liquid tolerance time was also significantly longer in the control group ( P = 0.006). There were no significant differences between the groups in solids tolerance time, opioid use, or hospital stay. Conclusions: Ultra-low-dose naloxone can effectively reduce postoperative ileus, improve opioid analgesia, and decrease side effects such as pruritus and nausea.
- 1 February 2026
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 15 (1)
Open AccessEffect of Ultra-low-dose Naloxone on Ileus after Cesarean Section: A Randomized Clinical Trial
Objective: Postoperative ileus commonly occurs after abdominal surgeries, often leading to longer hospital stays. While intravenous opioids are effective for pain management, they can extend ileus duration. Ultra-low-dose naloxone presents a promising strategy to improve pain control and minimize side effects. This study examines how ultra-low-dose naloxone impacts ileus after cesarean section. Methods: Seventy participants were randomly divided into two groups: 35 patients in the intervention group received a patient-controlled analgesia (PCA) pump with 30 mg of morphine, 0.25 μg/kg/h of naloxone, and saline, whereas 35 patients in the control group received morphine and saline only. Patients assessed their pain, nausea, and pruritus using a 0–10-point Visual Analog Scale upon arrival at the recovery room and then at 30 min, 60 min, 90 min, 120 min, 6 h, 12 h, and 24 h after surgery. We recorded the duration of ileus, time to tolerate liquids and solids, discharge timing, and analgesic consumption. Findings: The control group ( n = 35) experienced longer ileus duration ( P < 0.001), greater pain severity ( P = 0.02), and higher levels of nausea ( P = 0.04) and pruritus ( P = 0.02) compared to the intervention group ( n = 34). Liquid tolerance time was also significantly longer in the control group ( P = 0.006). There were no significant differences between the groups in solids tolerance time, opioid use, or hospital stay. Conclusions: Ultra-low-dose naloxone can effectively reduce postoperative ileus, improve opioid analgesia, and decrease side effects such as pruritus and nausea.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2025 (1) , 6669246
Three Episodes of Neuroleptic Malignant Syndrome With Risperidone: A Case Report and Literature Review
Background: Neuroleptic malignant syndrome (NMS) is an idiosyncratic and life‐threatening side effect that usually occurs in response to dopamine receptor antagonist medications. Despite increased awareness, the diagnosis of NMS remains challenging due to its wide differential diagnoses, which can lead to delayed treatment and increased mortality or premature reinitiation of the causative agent, culminating in recurrent NMS, a phenomenon with limited reports. This case presents a patient who experienced three episodes of NMS within 1 year, all triggered by risperidone. Case Presentation: A 58‐year‐old male patient with schizophrenia presented to the emergency department of a university hospital in Northern Iran, due to decreased consciousness, fever, and rigidity. Initial laboratory results showed elevated creatine phosphokinase (CPK) at 14,949 U/L. He had two previous episodes of rhabdomyolysis and hospitalization in the past year. Review of prior hospital records indicated treatment for rhabdomyolysis with symptoms consistent with NMS, without making this diagnosis. Conclusion: In any patient treated with dopaminergic drugs who suffer from mental status changes, muscle stiffness, high fever, and dysautonomia, especially who have complications such as rhabdomyolysis, kidney failure, seizures, leukocytosis, and increased CPK and lactate dehydrogenase (LDH), the possibility of NMS should be considered.
- 1 January 2025
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2025 (1) , 6669246
Open AccessThree Episodes of Neuroleptic Malignant Syndrome With Risperidone: A Case Report and Literature Review
Background: Neuroleptic malignant syndrome (NMS) is an idiosyncratic and life‐threatening side effect that usually occurs in response to dopamine receptor antagonist medications. Despite increased awareness, the diagnosis of NMS remains challenging due to its wide differential diagnoses, which can lead to delayed treatment and increased mortality or premature reinitiation of the causative agent, culminating in recurrent NMS, a phenomenon with limited reports. This case presents a patient who experienced three episodes of NMS within 1 year, all triggered by risperidone. Case Presentation: A 58‐year‐old male patient with schizophrenia presented to the emergency department of a university hospital in Northern Iran, due to decreased consciousness, fever, and rigidity. Initial laboratory results showed elevated creatine phosphokinase (CPK) at 14,949 U/L. He had two previous episodes of rhabdomyolysis and hospitalization in the past year. Review of prior hospital records indicated treatment for rhabdomyolysis with symptoms consistent with NMS, without making this diagnosis. Conclusion: In any patient treated with dopaminergic drugs who suffer from mental status changes, muscle stiffness, high fever, and dysautonomia, especially who have complications such as rhabdomyolysis, kidney failure, seizures, leukocytosis, and increased CPK and lactate dehydrogenase (LDH), the possibility of NMS should be considered.
- 5 December 2024
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (1) , e9-e17
The Effect of Dexmedetomidine on Inflammatory Factors and Clinical Outcomes in Patients With Septic Shock: A Randomized Clinical Trial
- 5 December 2024
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (1) , e9-e17
The Effect of Dexmedetomidine on Inflammatory Factors and Clinical Outcomes in Patients With Septic Shock: A Randomized Clinical Trial
- Open Access
- 15 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (7) , 3990-3997
Effect of erythropoietin on SOFA score, Glasgow Coma Scale and mortality in traumatic brain injury patients: a randomized-double-blind controlled trial
Background: Recent studies suggest that erythropoietin has an anti-inflammatory effect on the central nervous system. The authors aimed to investigate the effect of erythropoietin on Glasgow Coma Scale (GCS), Sequential Organ Failure Assessment (SOFA) scores, and the mortality rate of traumatic brain injury (TBI) patients. Methods: Sixty-eight patients with available inclusion criteria were randomly allocated to the control or intervention groups. In the intervention group, erythropoietin (4000 units) was administrated on days 1, 3, and 5. In the control group, normal saline on the same days was used. The primary outcomes were the GCS and SOFA score changes during the intervention. The secondary outcomes were the ventilation period during the first 2 weeks and the 3-month mortality rate. Results: Erythropoietin administration significantly affected SOFA score over time (P=0.008), but no significant effect on the GCS, and duration of ventilation between the two groups was observed. Finally, erythropoietin had no significant effect on the three-month mortality (23.5% vs. 38.2% in the erythropoietin and control group, respectively). However, the mortality rate in the intervention group was lower than in the control group. Conclusion: Our finding showed that erythropoietin administration in TBI may improve SOFA score. Therefore, erythropoietin may have beneficial effects on early morbidity and clinical improvement in TBI patients.
- 15 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (7) , 3990-3997
Open AccessEffect of erythropoietin on SOFA score, Glasgow Coma Scale and mortality in traumatic brain injury patients: a randomized-double-blind controlled trial
Background: Recent studies suggest that erythropoietin has an anti-inflammatory effect on the central nervous system. The authors aimed to investigate the effect of erythropoietin on Glasgow Coma Scale (GCS), Sequential Organ Failure Assessment (SOFA) scores, and the mortality rate of traumatic brain injury (TBI) patients. Methods: Sixty-eight patients with available inclusion criteria were randomly allocated to the control or intervention groups. In the intervention group, erythropoietin (4000 units) was administrated on days 1, 3, and 5. In the control group, normal saline on the same days was used. The primary outcomes were the GCS and SOFA score changes during the intervention. The secondary outcomes were the ventilation period during the first 2 weeks and the 3-month mortality rate. Results: Erythropoietin administration significantly affected SOFA score over time (P=0.008), but no significant effect on the GCS, and duration of ventilation between the two groups was observed. Finally, erythropoietin had no significant effect on the three-month mortality (23.5% vs. 38.2% in the erythropoietin and control group, respectively). However, the mortality rate in the intervention group was lower than in the control group. Conclusion: Our finding showed that erythropoietin administration in TBI may improve SOFA score. Therefore, erythropoietin may have beneficial effects on early morbidity and clinical improvement in TBI patients.
- Open Access
- 20 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (1) , 42-49
Evaluating the factors affecting clinical outcomes in critically ill COVID-19 unvaccinated patients admitted to the intensive care unit in a lower-middle-income country
Background: COVID-19, the most destructive pandemic of this century, caused the highest mortality rate among ICU patients. The evaluation of these patients is insufficient in lower-middle-income countries with limited resources during pandemics. As a result, our primary goal was to examine the characteristics of patients at baseline as well as their survival outcomes, and propose mortality predictors for identifying and managing the most vulnerable patients more effectively and quickly. Methods: A prospective analysis of COVID-19 ICU-admitted patients was conducted in our health care center in Iran, from April 1st until May 20th, 2020. Ninety-three patients were included in the study, and all were unvaccinated. A multi-variate logistic regression was conducted to evaluate mortality-associated factors. Results: There were 53 non-survivors among our ICU-admitted patients. The mean duration from symptoms’ onset to hospitalization was 6.92 ± 4.27 days, and from hospitalization to ICU admission was 2.52 ± 3.61 days. The average hospital stay for patients was 13.23 ± 10.43 days, with 8.84 ± 7.53 days in the ICU. Non-survivors were significantly older, had significantly lower hemoglobin levels and higher creatine phosphokinase (CPK) levels compared to survivors. They had marginally lower SpO2 levels at admission, higher vasopressor administrations, and were intubated more significantly during their ICU stay. The use of immunosuppressive drugs was also significantly higher in non-survivors. Logistic regression revealed that a one-point increase in APACHE II score at ICU admission increased mortality by 6%, and the presence of underlying diseases increased mortality by 4.27 times. Conclusion: We presented clinical mortality prediction factors for critically ill patients infected with COVID-19. Additional studies are necessary to identify more generalized mortality indicators for these patients in lower-middle-income countries. Export
- 20 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (1) , 42-49
Open AccessEvaluating the factors affecting clinical outcomes in critically ill COVID-19 unvaccinated patients admitted to the intensive care unit in a lower-middle-income country
Background: COVID-19, the most destructive pandemic of this century, caused the highest mortality rate among ICU patients. The evaluation of these patients is insufficient in lower-middle-income countries with limited resources during pandemics. As a result, our primary goal was to examine the characteristics of patients at baseline as well as their survival outcomes, and propose mortality predictors for identifying and managing the most vulnerable patients more effectively and quickly. Methods: A prospective analysis of COVID-19 ICU-admitted patients was conducted in our health care center in Iran, from April 1st until May 20th, 2020. Ninety-three patients were included in the study, and all were unvaccinated. A multi-variate logistic regression was conducted to evaluate mortality-associated factors. Results: There were 53 non-survivors among our ICU-admitted patients. The mean duration from symptoms’ onset to hospitalization was 6.92 ± 4.27 days, and from hospitalization to ICU admission was 2.52 ± 3.61 days. The average hospital stay for patients was 13.23 ± 10.43 days, with 8.84 ± 7.53 days in the ICU. Non-survivors were significantly older, had significantly lower hemoglobin levels and higher creatine phosphokinase (CPK) levels compared to survivors. They had marginally lower SpO2 levels at admission, higher vasopressor administrations, and were intubated more significantly during their ICU stay. The use of immunosuppressive drugs was also significantly higher in non-survivors. Logistic regression revealed that a one-point increase in APACHE II score at ICU admission increased mortality by 6%, and the presence of underlying diseases increased mortality by 4.27 times. Conclusion: We presented clinical mortality prediction factors for critically ill patients infected with COVID-19. Additional studies are necessary to identify more generalized mortality indicators for these patients in lower-middle-income countries. Export
- 18 November 2022
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (2) , 621-630
The blockade of transient receptor potential ankyrin 1 (TRPA1) protects against PTZ-induced seizure
Treatment of epilepsy remains a major problem as some epileptic patients do not respond to the current therapeutics. Transient receptor potential ankyrin 1 (TRPA1) belongs to the TRP channels and has diverse physiological functions in the body. Considering its physiological properties, we aimed to evaluate its role in two experimental models of epilepsy, including pentylenetetrazol (PTZ)-induced acute seizure and PTZ-evoked kindling. Furthermore, the TRPA1 protein levels were assessed in the cerebral cortex, hippocampus, and cerebellum after seizure induction. Three groups of Wistar rats received acute intraperitoneal injection of pentylenetetrazol (PTZ, 85 mg/kg). The groups received intraventricular injections of vehicle (dimethyl sulfoxide, Tween 80, and sterile 0.9% saline), valproate (30 µg/rat), or HC030031 (TRPA1 antagonist, 14 µg/rat) before PTZ injection. In the PTZ-induced kindling model, PTZ was administrated 35 mg/kg every other day for 24 days. PTZ gradually provoked seizure-related behaviors. After experiments, the TRPA1 levels in the brain were assessed using western blot. The results showed that HC030031 reduced the median of seizure scores and S5 duration while increasing S2 and S5 latencies in acute and kindling models. The anticonvulsant effect of HC030031 was comparable with valproate as a standard anticonvulsant drug. Furthermore, induction of seizure, either acute or kindling, enhanced TRPA1 levels in the cerebral cortex, hippocampus, and cerebellum that were prevented by HC030031 or valproate administration. The results of this study showed that HC030031 as a TRPA1 receptor antagonist promoted a significant anticonvulsant effect comparable with valproate. Both drugs prevented TRPA1 upregulation during seizures. These findings imply that TRPA1 is a potential target in treating epilepsy.
- 18 November 2022
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (2) , 621-630
The blockade of transient receptor potential ankyrin 1 (TRPA1) protects against PTZ-induced seizure
Treatment of epilepsy remains a major problem as some epileptic patients do not respond to the current therapeutics. Transient receptor potential ankyrin 1 (TRPA1) belongs to the TRP channels and has diverse physiological functions in the body. Considering its physiological properties, we aimed to evaluate its role in two experimental models of epilepsy, including pentylenetetrazol (PTZ)-induced acute seizure and PTZ-evoked kindling. Furthermore, the TRPA1 protein levels were assessed in the cerebral cortex, hippocampus, and cerebellum after seizure induction. Three groups of Wistar rats received acute intraperitoneal injection of pentylenetetrazol (PTZ, 85 mg/kg). The groups received intraventricular injections of vehicle (dimethyl sulfoxide, Tween 80, and sterile 0.9% saline), valproate (30 µg/rat), or HC030031 (TRPA1 antagonist, 14 µg/rat) before PTZ injection. In the PTZ-induced kindling model, PTZ was administrated 35 mg/kg every other day for 24 days. PTZ gradually provoked seizure-related behaviors. After experiments, the TRPA1 levels in the brain were assessed using western blot. The results showed that HC030031 reduced the median of seizure scores and S5 duration while increasing S2 and S5 latencies in acute and kindling models. The anticonvulsant effect of HC030031 was comparable with valproate as a standard anticonvulsant drug. Furthermore, induction of seizure, either acute or kindling, enhanced TRPA1 levels in the cerebral cortex, hippocampus, and cerebellum that were prevented by HC030031 or valproate administration. The results of this study showed that HC030031 as a TRPA1 receptor antagonist promoted a significant anticonvulsant effect comparable with valproate. Both drugs prevented TRPA1 upregulation during seizures. These findings imply that TRPA1 is a potential target in treating epilepsy.
- Open Access
- 10 March 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 76, 103492
Melatonin as adjunctive therapy in patients admitted to the Covid-19
Coronavirus has disrupted the natural order of the world since September 2019 with no specific medication. The beneficial effects of melatonin on sepsis and viral influenza were demonstrated previously, but its effects on covid-19, especially COVID -19 ICU, is unclear. Therefore, our aim was to determine the effects of melatonin in COVID-19 ICU patients. This is a retrospective cohort study in which the records of patients admitted to COVID -19 ICU of (XXX) during March to June 2020 were reviewed. According to inclusion criteria, patients who received 15 mg of melatonin daily were called MRG and the rest were called NMRG. Thirty-one patients were included and analyzed, of which twelve patients were in MRG. Demographic and clinical characteristics, and laboratory data were similar between two groups at ICU admission. Melatonin had no significant effect on ICU duration, CRP and ESR, also the trend of changes was in favor of melatonin. Nevertheless, melatonin significantly reduced the NLR (OR = −9.81, p = 0.003), and also declined mortality marginally (p = 0.09). Melatonin was well tolerated with no major adverse effects, moreover the thrombocytopenia occurrence was significantly lower in MRG (p = 0.005). In MRG, survival increased and mortality risk decreased, although the difference between groups wasn't significant (p = 0.37), which might be related to the small sample-size. Our study showed that melatonin is unlikely to reduce mortality among COVID19 patients and with no significant effect on disease-specific biochemical parameters.
- 10 March 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 76, 103492
Open AccessMelatonin as adjunctive therapy in patients admitted to the Covid-19
Coronavirus has disrupted the natural order of the world since September 2019 with no specific medication. The beneficial effects of melatonin on sepsis and viral influenza were demonstrated previously, but its effects on covid-19, especially COVID -19 ICU, is unclear. Therefore, our aim was to determine the effects of melatonin in COVID-19 ICU patients. This is a retrospective cohort study in which the records of patients admitted to COVID -19 ICU of (XXX) during March to June 2020 were reviewed. According to inclusion criteria, patients who received 15 mg of melatonin daily were called MRG and the rest were called NMRG. Thirty-one patients were included and analyzed, of which twelve patients were in MRG. Demographic and clinical characteristics, and laboratory data were similar between two groups at ICU admission. Melatonin had no significant effect on ICU duration, CRP and ESR, also the trend of changes was in favor of melatonin. Nevertheless, melatonin significantly reduced the NLR (OR = −9.81, p = 0.003), and also declined mortality marginally (p = 0.09). Melatonin was well tolerated with no major adverse effects, moreover the thrombocytopenia occurrence was significantly lower in MRG (p = 0.005). In MRG, survival increased and mortality risk decreased, although the difference between groups wasn't significant (p = 0.37), which might be related to the small sample-size. Our study showed that melatonin is unlikely to reduce mortality among COVID19 patients and with no significant effect on disease-specific biochemical parameters.
- 1 December 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (6) , 103285
Association of VLA4, 5, 6 and PSGL1 expression levels with engraftment in autologous HPSC transplantation in multiple myeloma patients
- 1 December 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (6) , 103285
Association of VLA4, 5, 6 and PSGL1 expression levels with engraftment in autologous HPSC transplantation in multiple myeloma patients